Value
7.9/10data confidence 67%| Component | Sub-score |
|---|---|
| P/S | 9.9 |
| Fwd P/E | 6.5 |
| PEG | 10.0 |
| Analyst target | 3.0 |
- ▸Forward P/E: 19.6x
- ▸PEG: 0.16
- ▸Attractively valued
OSCR · Why this verdict
Why Oscar Health (OSCR) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.7/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Oscar Health is posting impressive 53% revenue growth and is the industry growth leader in healthcare plans, but 93% revenue concentration in government premium payments creates existential policy risk, and business quality at 2.9 remains well below the 4.0 investability floor.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Quality scored 2.9 against a 4.0 minimum threshold, driven by very low return on assets, near-zero net margin, and a Piotroski F-Score of 6/9, placing the company below the quality floor for standard position eligibility. Quality breakdown | Quality score rises above 4.0 as operating margin expands above 5% and net margin turns consistently positive within 12 months. | →Stable |
| CounterHealthcare plan operators run at thin margins by design; the appropriate comparison is the medical loss ratio trajectory, not absolute margin levels versus non-insurance peers. | ||
Oscar Health delivered 53% year-over-year revenue growth, placing it as the industry growth leader in healthcare plans, reflecting successful member enrollment expansion. Growth breakdown | Revenue growth remains above 20% for at least 2 consecutive quarters over the next 12 months. | →Stable |
| CounterRevenue growth at this rate in government-sponsored insurance markets is heavily dependent on CMS rate increases and enrollment subsidies that can be reduced by policy changes. | ||
CMS premiums account for 93% of all revenue, creating a single-source concentration risk where any reduction in CMS reimbursement rates, enrollment subsidies, or marketplace participation rules could substantially impair the business model. Bear case | Revenue diversification improves such that government-payer concentration falls below 85% within 24 months. | →Stable |
| CounterSpecialist government health plan operators can earn strong returns precisely because they build deep operational expertise in navigating CMS regulations that generalist insurers lack. | ||
The company produced a massive 88% earnings beat in the most recent quarter followed by a 35% miss the quarter prior, indicating high earnings unpredictability that makes forward planning unreliable. Earnings | Earnings surprise standard deviation narrows with 3 consecutive quarters of surprise within plus or minus 15% of estimates. | →Stable |
| CounterThe recent 88% earnings beat ($2.07 vs $1.10 estimate) reflects genuine operational improvement in medical loss ratios that may be the inflection point the market is awaiting. | ||
Quality scored 2.9 against a 4.0 minimum threshold, driven by very low return on assets, near-zero net margin, and a Piotroski F-Score of 6/9, placing the company below the quality floor for standard position eligibility.
→StableQuality breakdown
- Expectation
- Quality score rises above 4.0 as operating margin expands above 5% and net margin turns consistently positive within 12 months.
CounterHealthcare plan operators run at thin margins by design; the appropriate comparison is the medical loss ratio trajectory, not absolute margin levels versus non-insurance peers.
Oscar Health delivered 53% year-over-year revenue growth, placing it as the industry growth leader in healthcare plans, reflecting successful member enrollment expansion.
→StableGrowth breakdown
- Expectation
- Revenue growth remains above 20% for at least 2 consecutive quarters over the next 12 months.
CounterRevenue growth at this rate in government-sponsored insurance markets is heavily dependent on CMS rate increases and enrollment subsidies that can be reduced by policy changes.
CMS premiums account for 93% of all revenue, creating a single-source concentration risk where any reduction in CMS reimbursement rates, enrollment subsidies, or marketplace participation rules could substantially impair the business model.
→StableBear case
- Expectation
- Revenue diversification improves such that government-payer concentration falls below 85% within 24 months.
CounterSpecialist government health plan operators can earn strong returns precisely because they build deep operational expertise in navigating CMS regulations that generalist insurers lack.
The company produced a massive 88% earnings beat in the most recent quarter followed by a 35% miss the quarter prior, indicating high earnings unpredictability that makes forward planning unreliable.
→StableEarnings
- Expectation
- Earnings surprise standard deviation narrows with 3 consecutive quarters of surprise within plus or minus 15% of estimates.
CounterThe recent 88% earnings beat ($2.07 vs $1.10 estimate) reflects genuine operational improvement in medical loss ratios that may be the inflection point the market is awaiting.
Per-dimension breakdown
Quality
2.9/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.1 |
| Gross margin | 0.0 |
| Op margin | 6.1 |
| Net margin | 0.0 |
| Current ratio | 4.3 |
| Moat | 5.8 |
| Piotroski F | 6.7 |
- ▸Quality concerns
Growth
10.0/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 10.0 |
| EPS growth | 10.0 |
- ▸Strong growth: 53% YoY
Momentum
5.3/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.5 |
| MACD | 3.0 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 0.0 |
- ▸Overbought (RSI 70)
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
4.0/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 5.0 |
| Price target | 2.3 |
| erm sentiment | 4.7 |
- ▸Below analyst target
Insider
4.7/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 6.5 |
| insider conviction | 2.4 |
| holder change | 5.1 |
- ▸Modest insider buying — $4,883,422 (0.056% of mkt cap)
Peer rank
4.7/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 3.6 |
| quality rank | 1.8 |
| growth rank | 8.2 |
- ▸Industry growth leader
Technical
4.7/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 3.5 |
| support resistance | 2.1 |
| 52w position | 8.6 |
Risk (lower is worse)
4.0/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 6.3 |
| days to cover | 8.7 |
| volatility | 0.0 |
| put call | 3.0 |
| implied vol | 0.0 |
| max pain risk | 3.0 |
| beta | 2.0 |
| debt equity | 8.8 |
- ▸Elevated put/call: 1.55
- ▸High IV: 84%
- ▸Above max pain $11
- ▸Concentration risks: 2 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
6.1/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 6.5 |
| earnings history | 3.3 |
| earnings timing | 5.0 |
| surprise avg | 9.5 |
- ▸Earnings concerns: 2B/2M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (6)
- MOMENTUM:5.3>=4.5
- INSIDER:OK
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:46d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (2)
- ASYMMETRY:-2.0=NEGATIVE
- HEALTHCARE_GOV_PAYER:HARD_BLOCK
Warning (2)
- MOMENTUM:5.3<5.5 (soft — BUY_NOW allowed but watch)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
-2.03
Upside
-30.4%
Downside
15.0%
Sizing output
AVOID
SetupUNKNOWN — No clear chart pattern; technical signals are mixed
EdgeNO_EDGE — No clear edge identified
SuitabilityAGGRESSIVE — Beta 2.39>1.3
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Growth at 10.0 could not lift the engine output above the verdict floor. Failed gate signal: ASYMMETRY:-2.0=NEGATIVE.
The strongest dimensions are Growth at 10.0, Value at 7.9, and Catalyst at 6.1; the weakest are Quality at 2.9, Risk (lower is worse) at 4.0, and Sentiment at 4.0. The V9 engine flagged 2 failed gates with 2 warnings, producing an asymmetric reward-to-risk of -2.03 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Oscar Health delivered 53% year-over-year revenue growth, placing it as the industry growth leader in healthcare plans, reflecting successful member enrollment expansion.
Trip ifRevenue growth falls below 10% for 2 consecutive quarters.
- P2CMS premiums account for 93% of all revenue, creating a single-source concentration risk where any reduction in CMS reimbursement rates, enrollment subsidies, or marketplace participation rules could substantially impair the business model.
Trip ifCMS reimbursement rates decline by more than 3% or enrollment subsidies are reduced by more than 20% in a policy change announcement.
- P3Quality scored 2.9 against a 4.0 minimum threshold, driven by very low return on assets, near-zero net margin, and a Piotroski F-Score of 6/9, placing the company below the quality floor for standard position eligibility.
Trip ifOperating margin falls below 3% for 2 consecutive quarters after the most recent improvement.
- P4The company produced a massive 88% earnings beat in the most recent quarter followed by a 35% miss the quarter prior, indicating high earnings unpredictability that makes forward planning unreliable.
Trip ifEarnings miss exceeds negative 30% for 2 of the next 4 quarters.